{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:17:12Z","timestamp":1788369432188,"version":"build-2803163510"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Else Kr\u00f6ner Fresenius Stiftung","award":["2019_Kolleg_14"],"award-info":[{"award-number":["2019_Kolleg_14"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma harbors frequent alterations in the retinoblastoma pathway, providing a genetic rationale for therapeutic targeting with cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors. The NOA-20 trial did not reveal a progression-free survival benefit of CDK4\/6 inhibition plus radiation therapy in newly diagnosed, O6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma. In fact, CDK4\/6 inhibitor monotherapy has not demonstrated efficacy in solid tumors. We aimed at discovering response modulators to CDK4\/6 inhibition, paving the way for rational combination therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted genome-wide CRISPR-Cas9 screens in human glioma cell lines and stem-like cells (LN229, LN18, LNZ308, T98G, and GS-9) under CDK4\/6 inhibition, employing knockout (Brunello library) and activation strategies (Calabrese library), followed by genetic and pharmacological validation of selected candidate genes in vitro and ex vivo (primary cultures) as well as the investigation of 1 functionally instructed combination therapy in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Loss of AMBRA1 and gain of function of CCNE1 reduced sensitivity to CDK4\/6 inhibition in glioma cells, whereas disruption of checkpoint kinase 1 (CHEK1) or FAM122A resulted in synthetic lethality in combination with CDK4\/6 inhibition. AMBRA1-deficient glioma cells exhibited increased sensitivity to CHK1 inhibition, revealing a context-specific vulnerability. Combined inhibition of CHK1 and CDK4\/6 led to synergistic antiglioma activity in vitro, ex vivo, and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data identify AMBRA1, CCNE1, CHEK1, and FAM122A as potential molecular modifiers of CDK4\/6 inhibition response in experimental glioma and provide a biological rationale for combinatorial targeting with CDK4\/6 inhibition in glioblastoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag093","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:12:33Z","timestamp":1777637553000},"page":"1904-1920","source":"Crossref","is-referenced-by-count":1,"title":["Molecular modulators of cyclin-dependent kinase 4\/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6638-4414","authenticated-orcid":false,"given":"Surender","family":"Surender","sequence":"first","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, A Partnership Between DKFZ and University Hospital T\u00fcbingen , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-4280","authenticated-orcid":false,"given":"Lara Annina","family":"Haeusser","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, A Partnership Between DKFZ and University Hospital T\u00fcbingen , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Kuhlburger","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Quantitative Biology Center, Eberhard Karls University T\u00fcbingen , T\u00fcbingen,","place":["Germany"]},{"name":"Biomedical Data Science, Department of Computer Science, Eberhard Karls University T\u00fcbingen , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6070-0434","authenticated-orcid":false,"given":"Foteini","family":"Tsiami","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-2943","authenticated-orcid":false,"given":"Nihal Olcay","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4918-9502","authenticated-orcid":false,"given":"Louise","family":"Maise","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0691","authenticated-orcid":false,"given":"Sven","family":"Nahnsen","sequence":"additional","affiliation":[{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Quantitative Biology Center, Eberhard Karls University T\u00fcbingen , T\u00fcbingen,","place":["Germany"]},{"name":"Biomedical Data Science, Department of Computer Science, Eberhard Karls University T\u00fcbingen , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-6919","authenticated-orcid":false,"given":"Daniel Josef","family":"Merk","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-8782","authenticated-orcid":false,"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital T\u00fcbingen, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, A Partnership Between DKFZ and University Hospital T\u00fcbingen , T\u00fcbingen,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen Stuttgart, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026080501522634200_noag093-B1","doi-asserted-by":"publisher","first-page":"V1","DOI":"10.1093\/NEUONC\/NOAC202","article-title":"CBTRUS statistical report: primary brain and other Central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026080501522634200_noag093-B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMOA043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080501522634200_noag093-B3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMOA1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080501522634200_noag093-B4","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/JAMA.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"2026080501522634200_noag093-B5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026080501522634200_noag093-B6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/J.CCR.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"2026080501522634200_noag093-B7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/NATURE07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"2026080501522634200_noag093-B8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/S40268-017-0180-1","article-title":"Revisiting CDK inhibitors for treatment of glioblastoma multiforme","volume":"17","author":"Lubanska","year":"2017","journal-title":"Drugs R D"},{"key":"2026080501522634200_noag093-B9","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-17-0803","article-title":"Combined CDK4\/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms","volume":"23","author":"Olmez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026080501522634200_noag093-B10","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/J.CCELL.2024.08.006","article-title":"GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"2026080501522634200_noag093-B11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/S11060-018-2977-3","article-title":"Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma","volume":"140","author":"Taylor","year":"2018","journal-title":"J Neurooncol"},{"key":"2026080501522634200_noag093-B12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1124\/dmd.114.062745","article-title":"Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft","volume":"43","author":"Raub","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"2026080501522634200_noag093-B13","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","article-title":"A phase 0 trial of ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic- and pharmacokinetic-guided expansion cohort","volume":"25","author":"Tien","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026080501522634200_noag093-B14","doi-asserted-by":"publisher","first-page":"55319","DOI":"10.18632\/ONCOTARGET.19429","article-title":"CDK4\/6 inhibition is more active against the glioblastoma proneural subtype","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"2026080501522634200_noag093-B15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41523-018-0092-4","article-title":"Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer","volume":"4","author":"Guarducci","year":"2018","journal-title":"NPJ Breast Cancer 2018 Cancer"},{"key":"2026080501522634200_noag093-B16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925\/SUPPL_FILE\/PROTOCOL_JCO.18.00925.PDF","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080501522634200_noag093-B17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/S13059-024-03438-W\/FIGURES\/7","article-title":"Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors","volume":"25","author":"Merk","year":"2024","journal-title":"Genome Biol"},{"key":"2026080501522634200_noag093-B18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-22-2206","article-title":"CCNE1 and PLK1 mediate resistance to palbociclib in HR+\/HER2\u2212 metastatic breast cancer","volume":"29","author":"Guerrero-Zotano","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026080501522634200_noag093-B19","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-025-03928-9","article-title":"Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial","volume":"31","author":"Wick","year":"2025","journal-title":"Nat Med"},{"key":"2026080501522634200_noag093-B20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/NBT.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2026080501522634200_noag093-B21","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1038\/S41467-018-07901-8","article-title":"Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities","volume":"9","author":"Sanson","year":"2018","journal-title":"Nat Commun"},{"key":"2026080501522634200_noag093-B22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1186\/S13059-014-0554-4\/TABLES\/2","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol"},{"key":"2026080501522634200_noag093-B23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.15252\/MSB.20145216","article-title":"Measuring error rates in genomic perturbation screens: gold standards for human functional genomics","volume":"10","author":"Hart","year":"2014","journal-title":"Mol Syst Biol"},{"key":"2026080501522634200_noag093-B24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/S13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026080501522634200_noag093-B25","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/NEUONC\/NOAE278","article-title":"Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma","volume":"27","author":"Haeusser","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026080501522634200_noag093-B26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/S13046-024-02995-Z","article-title":"Functionally-instructed modifiers of response to ATR inhibition in experimental glioma","volume":"43","author":"Walter","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"2026080501522634200_noag093-B27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/J.CELL.2019.11.036","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"key":"2026080501522634200_noag093-B28","doi-asserted-by":"publisher","first-page":"116140","DOI":"10.1016\/J.CELREP.2025.116140","article-title":"Targeting CDK2 for cancer therapy","volume":"44","author":"Knudsen","year":"2025","journal-title":"Cell Rep"},{"key":"2026080501522634200_noag093-B29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/S41698-022-00311-6","article-title":"Co-targeting CDK2 and CDK4\/6 overcomes resistance to aromatase and CDK4\/6 inhibitors in ER+ breast cancer","volume":"6","author":"Al-Qasem","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026080501522634200_noag093-B30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41586-021-03474-7","article-title":"The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D","volume":"592","author":"Chaikovsky","year":"2021","journal-title":"Nature"},{"key":"2026080501522634200_noag093-B31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-021-03422-5","article-title":"AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity","volume":"592","author":"Maiani","year":"2021","journal-title":"Nature"},{"key":"2026080501522634200_noag093-B32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41586-021-03445-y","article-title":"CRL4AMBRA1 is a master regulator of D-type cyclins","volume":"592","author":"Simoneschi","year":"2021","journal-title":"Nature"},{"key":"2026080501522634200_noag093-B33","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.1038\/SJ.ONC.1210868","article-title":"DNA double-strand breaks: their cellular and clinical impact?","volume":"26","author":"Jeggo","year":"2007","journal-title":"Oncogene"},{"key":"2026080501522634200_noag093-B34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.molcel.2020.10.008","article-title":"CHK1 inhibitor blocks phosphorylation of FAM122A and promotes replication stress","volume":"80","author":"Li","year":"2020","journal-title":"Mol Cell"},{"key":"2026080501522634200_noag093-B35","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.1038\/s41467-024-50015-7","article-title":"FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55\u03b1\/PP2A through helical motifs","volume":"15","author":"Wasserman","year":"2024","journal-title":"Nat Commun"},{"key":"2026080501522634200_noag093-B36","doi-asserted-by":"publisher","first-page":"e108599","DOI":"10.15252\/EMBJ.2021108599","article-title":"CDK4\/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal","volume":"41","author":"Crozier","year":"2022","journal-title":"Embo J"},{"key":"2026080501522634200_noag093-B37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/J.CELL.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"2026080501522634200_noag093-B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-28372-y","article-title":"Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target","volume":"13","author":"Abdelfattah","year":"2022","journal-title":"Nat Commun"},{"key":"2026080501522634200_noag093-B39","doi-asserted-by":"publisher","first-page":"F379","DOI":"10.1152\/AJPRENAL.00475.2013","article-title":"CDK4\/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury","volume":"306","author":"Dirocco","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026080501522634200_noag093-B40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/J.JPHA.2022.05.003","article-title":"Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS\/MS","volume":"12","author":"Margaryan","year":"2022","journal-title":"J Pharm Anal"},{"key":"2026080501522634200_noag093-B41","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.18632\/ONCOTARGET.27238","article-title":"Central nervous system-specific efficacy of CDK4\/6 inhibitors in randomized controlled trials for metastatic breast cancer","volume":"10","author":"Nguyen","year":"2019","journal-title":"Oncotarget"},{"key":"2026080501522634200_noag093-B42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMOA1505270\/SUPPL_FILE\/NEJMOA1505270_DISCLOSURES.PDF","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080501522634200_noag093-B43","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026080501522634200_noag093-B44","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1158\/2767-9764.CRC-24-0247","article-title":"A kinome-wide synthetic lethal CRISPR\/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4\/CDK6 blockade in HNSCC","volume":"4","author":"Goto","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026080501522634200_noag093-B45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/S41419-022-04569-3","article-title":"Genome wide CRISPR\/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence","volume":"13","author":"Carpintero-Fern\u00e1ndez","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026080501522634200_noag093-B46","doi-asserted-by":"publisher","first-page":"9550","DOI":"10.1038\/S41467-024-53837-7","article-title":"Inhibition of GPX4 enhances CDK4\/6 inhibitor and endocrine therapy activity in breast cancer","volume":"15","author":"Herrera-Abreu","year":"2024","journal-title":"Nat Commun"},{"key":"2026080501522634200_noag093-B47","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/J.CCELL.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor","volume":"39","author":"Freeman-Cook","year":"2021","journal-title":"Cancer Cell"},{"key":"2026080501522634200_noag093-B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-45796-w","article-title":"MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation","volume":"15","author":"Ma","year":"2024","journal-title":"Nat Commun"},{"key":"2026080501522634200_noag093-B49","doi-asserted-by":"publisher","first-page":"113198","DOI":"10.1016\/J.CELREP.2023.113198","article-title":"Sequential activation of E2F via Rb degradation and c-myc drives resistance to CDK4\/6 inhibitors in breast cancer","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep"},{"key":"2026080501522634200_noag093-B50","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor\u2013positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080501522634200_noag093-B51","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/J.CCELL.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"key":"2026080501522634200_noag093-B52","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/SJ.ONC.1208613","article-title":"Cyclin E in normal and neoplastic cell cycles","volume":"24","author":"Hwang","year":"2005","journal-title":"Oncogene"},{"key":"2026080501522634200_noag093-B53","doi-asserted-by":"publisher","first-page":"15658","DOI":"10.18632\/ONCOTARGET.24585","article-title":"CDK4\/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer","volume":"9","author":"Iyengar","year":"2018","journal-title":"Oncotarget"},{"key":"2026080501522634200_noag093-B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-019-0147-x","article-title":"Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death","volume":"8","author":"van Harten","year":"2019","journal-title":"Oncogenesis"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag093\/68210472\/noag093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/8\/1904\/68210472\/noag093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/8\/1904\/68210472\/noag093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:52:38Z","timestamp":1785909158000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/8\/1904\/8667287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag093","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,4]]}}}